<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For Quarter Ended Commission File No.
MARCH 31, 1998 0-26770
-------------- -------------
NOVAVAX, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 22-2816046
-------- ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
8320 GUILFORD ROAD, COLUMBIA, MD 21046
-------------------------------- --------
(Address of principal executive offices) (Zip code)
(301) 854-3900
--------------
Registrant's telephone number, including area code
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that
the Registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes X No
--- ---
The number of shares outstanding of each of the issuer's classes of common
stock, as of the latest practicable date:
Common Shares Outstanding at May 8, 1998
12,071,471
<PAGE> 2
NOVAVAX, INC AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(unaudited)
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
1998 1997
---- ----
<S> <C> <C>
ASSETS
Current Assets:
Cash and Cash Equivalents $ 9,188,116 $ 3,847,107
Accounts receivable 176,679 217,150
Receivable from former parent 32,835 32,835
Prepaid expenses and other current assets 147,162 205,952
----------- -----------
Total current assets 9,544,792 4,303,044
----------- -----------
Property and equipment - cost 1,562,790 1,428,638
Accumulated depreciation (574,148) (539,463)
----------- -----------
Property and equipment - net 988,642 889,175
Patent costs, net of accumulated amortization of
$581,637 and $549,397 in 1998 and 1997
respectively 1,568,340 1,573,454
Other assets 16,959 57,598
----------- -----------
Total assets $12,118,733 $ 6,823,271
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Capital Lease Obligations 32,229 10,744
Accounts payable 168,333 237,884
Accrued payroll 72,096 40,010
----------- -----------
Total current liabilities 272,658 288,638
Capital lease obligations, less current maturities 35,631 12,863
----------- -----------
Stockholders' Equity:
Preferred stock, $.01 par value, 2,000,000
shares authorized; 6,500 designated as Series A
Custom Convertible Preferred Stock; 6,500 shares
issued and outstanding at March 31, 1998; none
issued and outstanding at December 31, 1997. 5,997,599 -
Common stock, $.01 par value, 30,000,000
shares authorized; 12,082,687 issued and
12,062,943 outstanding at March 31, 1998;
12,031,757 and 12,012,013 shares issued and
outstanding at December 31, 1997 120,827 120,318
Additional paid-in capital 38,142,212 38,020,621
Accumulated deficit (32,176,379) (31,342,780)
Deferred compensation on stock options granted (23,046) (25,620)
Treasury stock, 19,744 shares, cost basis (250,769) (250,769)
----------- -----------
Total stockholders' equity 11,810,444 6,521,770
Total liabilities and stockholders' equity $12,118,733 $ 6,823,271
=========== ===========
</TABLE>
The accompanying notes are an integral part of the consolidated
financial statements.
1
<PAGE> 3
NOVAVAX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 1998 AND 1997
(unaudited)
<TABLE>
<CAPTION>
1998 1997
---- ----
<S> <C> <C>
Revenues:
Contract Revenue $ 204,664 $ -
Operating expenses:
General and administrative 536,921 642,253
Research and development 594,379 601,623
----------- -----------
Total operating expenses 1,131,300 1,243,876
Loss from operations (926,636) (1,243,876)
----------- -----------
Interest income, net 93,037 34,254
Net loss (833,599) (1,209,622)
Preferred stock deemed dividend (455,048) -
----------- -----------
Net loss applicable to common stockholders $(1,288,647) $(1,209,622)
=========== ===========
Per common share (basic and diluted):
Net loss before preferred stock dividend requirements $ (0.07) $ (0.11)
Preferred stock dividend requirements (0.04) -
----------- -----------
Net loss applicable to common stockholders $ (0.11) $ (0.11)
=========== ===========
Weighted average number of common shares outstanding
(basic and diluted) 12,036,552 10,889,546
=========== ===========
</TABLE>
The accompanying notes are an integral part of the consolidated
financial statements.
2
<PAGE> 4
NOVAVAX, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 1998 AND 1997
(unaudited)
<TABLE>
<CAPTION>
1998 1997
---- ----
<S> <C> <C>
Cash flows from operating activities:
Net Loss applicable to common stockholders $ (833,599) $(1,209,622)
Reconciliation of net loss to net cash used by operating activities:
Non-cash compensation expense 2,574 144,411
Depreciation and amortization 66,925 67,862
Issuance of stock to 401(k) plan - 2,499
Changes in operating assets and liabilities
Accounts receivable 40,471 -
Prepaid expenses and other assets 99,429 96,858
Payable to/receivable from former parent - (6,176)
Accounts payable and accrued expenses (37,465) (209,497)
---------- -----------
Net cash used by operating activities (661,665) (1,113,665)
Cash flows from investing activities:
Proceeds from the sale of marketable securities - 500,820
Capital expenditures (83,807) (30,317)
Deferred patent costs (27,126) (44,256)
---------- -----------
Net cash provided by (used by) investing activities (110,933) 426,247
Cashflows from financing activities:
Payment of capital lease obligations (6,092) (2,551)
Proceeds from the private placement of Preferred Stock 5,997,599
Proceeds from the private placement of Common Stock 5,002,718
Proceeds from the exercise of options 122,100 47,062
---------- -----------
Net cash provided by financing activities 6,113,607 5,047,229
---------- -----------
Net change in cash and cash equivalents 5,341,009 4,359,811
Cash and cash equivalents at beginning of the period 3,847,107 2,481,258
---------- -----------
Cash and cash equivalents at end of the period $9,188,116 $ 6,841,069
========== ===========
</TABLE>
The accompanying notes are an integral part of the consolidated
financial statements.
3
<PAGE> 5
NOVAVAX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation
The accompanying consolidated financial statements include the accounts of
Novavax its wholly owned subsidiaries, Micro-Pak, Inc. and Micro Vesicular
Systems, Inc. and Lipovax, Inc. All significant intercompany accounts and
transactions have been eliminated. These statements have been prepared by
Novavax, Inc. without audit, pursuant to the rules and regulations of the
Securities and Exchange Commission, and reflect all adjustments, which, in the
opinion of management, are necessary for a fair presentation of the results for
the interim periods, presented. All such adjustments are of a normal recurring
nature.
Certain information in footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
has been condensed or omitted pursuant to such rules and regulations, although
the Company believes the disclosures are adequate to make the information
presented not misleading. It is suggested that these financial statements are
read in conjunction with the financial statements and the notes thereto
included in the Company's Annual Report on Form 10-K/A for the year ended
December 31, 1997.
2. Net Loss Per Share
In 1997, the Company adopted SFAS No. 128, Earnings per Share. Basic earnings
per share are computed by dividing the net loss available to common
stockholders by the weighted average number of common shares outstanding during
the period. Diluted earnings per share is computed by dividing net earnings
available to common stockholders by the weighted average number of common
shares outstanding after giving effect to all dilutive potential common shares
that were outstanding during the period.
Potential dilutive common shares are not included in the computation of diluted
earnings per share if they are antidilutive. Net loss per share as reported was
not adjusted for potential common shares, as they are antidilutive. Earnings
per share for all other periods presented conform to SFAS No. 128.
3. New Accounting Standards
The Financial Accounting Standards Board has issued a new standard that became
effective in reporting periods beginning after December 15, 1997. SFAS No. 130,
Reporting Comprehensive Income, requires additional reporting with respect to
certain changes in assets and liabilities that previously were not required to
be reported as results of operations for the period. The Company's adoption of
SFAS No. 130 resulted in no additional reporting as the Company has no other
items of comprehensive income or loss.
4
<PAGE> 6
NOVAVAX, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
4. Employee Benefit Plan
Effective January 1, 1997, the Company established the Novavax, Inc. 401(k)
Profit Sharing Plan (the "Plan"). The Plan is a discretionary defined
contribution plan and covers all employees who were employed by the Company on
or after January 1, 1997 and who have completed three months of service to the
Company. Under the provisions of the Plan, employees may contribute up to
$9,500 of their annual base compensation on the tax-deferred basis. The Board
of Directors determines the Company's matching contribution in any year. As of
March 31, 1998 and 1997, the Company accrued contributions of Company stock
valued at $4,438 and $2,500, respectively.
5. Financing Transactions
On February 10, 1997, Novavax signed a definitive agreement to privately place
1,200,000 common shares with Anaconda Opportunity Fund L.P. Novavax also
granted warrants to purchase an additional 600,000 shares at a price of $6.00
per share and 600,000 shares at a price of $8.00 per share. The warrants have a
three-year term. The transaction was closed on March 14, 1997 at an aggregate
price of $5,100,000. Proceeds net of all related transaction costs were
$5,002,718.
On January 23, 1998, the Company entered into Subscription Agreements to
effectuate the private placement of 6,500 shares of Series A Custom Convertible
Preferred Stock, $.01 par value per share (the "Preferred Stock"). The closing
occurred on January 28, 1998 (the "Issuance Date") at an aggregate purchase
price of $6,500,000. Proceeds net of all related transaction costs were
$5,997,599.
The Preferred Stock is convertible into shares of Common Stock at a conversion
price equal to (i) during a period of 90 days following the Issuance Date, 100%
of the average of the two lowest consecutive trade prices of the Common Stock
as reported on the American Stock Exchange for the 25 trading days immediately
preceding the conversion date (the "Two Day Average Trading Price") or (ii)
during the period on and after the date which is 91 days after the Issuance
Date, 94% of the Two Day Average Trading Price (the "Conversion Price").
From the Issuance Date, there is ceiling price of $6.33 and within the first
180 days after the Issuance Date, the Conversion Price has applicable floor
prices based on conversion dates. The floor prices range from $5.67 to $4.32.
The maximum number of shares as measured by the conversion terms most
beneficial to the holders of the Preferred Stock at the time of closing
resulted in a deemed dividend in the amount of $455,048 for the three months
ended March 31, 1998.
5
<PAGE> 7
NOVAVAX, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS
The following discussion may contain statements that are not purely historical.
Certain statements contained herein or as may otherwise be incorporated by
reference herein constitute "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include but are not limited to statements regarding future product
development and related clinical trials and statements regarding future
research and development. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the Company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements.
Such factors include, among other things, the following: general economic and
business conditions; competition; unexpected changes in technologies and
technological advances; ability to obtain rights to technology; ability to
obtain and enforce patents; ability to commercialize and manufacture products;
statements regarding establishment of commercial-scale manufacturing
capabilities, and statements regarding future collaborations with industry
partners. results of preclinical studies; results of research and development
activities; business abilities and judgment of personnel; availability of
qualified personnel; changes in, or failure to comply with, governmental
regulations; ability to obtain adequate financing in the future; and other
factors referenced herein.
All forward-looking statements included in this document are based on
information available to the Company on the date hereof, and the Company
assumes no obligation to update any such forward-looking statements.
Accordingly, past results and trends should not be used by investors to
anticipate future results or trends.
The following is a discussion of the historical consolidated financial
condition and results of operations of Novavax and its subsidiaries and should
be read in conjunction with the consolidated financial statements and notes
thereto set forth in this Form 10Q. Additional information concerning factors
that could cause actual results to differ materially from those in the
forward-looking statements is contained from time to time in the Company's SEC
filings, including but not limited to the Company's report on Form 10-K/A for
the year ended December 31, 1997.
RESULTS OF OPERATIONS
The Company has incurred net losses since its inception from the development of
its technologies for human pharmaceuticals, vaccines and vaccine adjuvants.
Novavax expects the losses to increase in the near-term as it conducts
additional human clinical trials and seeks regulatory approval for its product
candidates. The Company also expects to continue to incur substantial operating
losses over the extensive time period required to develop the Company's
products, or until such time as revenues, to offset the costs, are sufficient
to fund its continuing operations.
6
<PAGE> 8
NOVAVAX, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 1998 COMPARED TO 1997
The net loss before the preferred stock deemed dividend of $455,048 was
$833,599 for the quarter ended March 31, 1998. This compares to a net loss in
the prior year of $1,209,622. The reduction of $376,023 was due primarily to
increases in revenue of $204,664, decreases in general and administrative
expenses of $105,332 and increases in interest income of $58,783.
The net loss applicable to common stockholders of $1,288,647 for the quarter
ended March 31, 1998, was $79,025 more than the net loss of $1,209,622 in the
quarter ended March 31, 1997 and reflects those items mentioned in the above
paragraph along with a preferred stock deemed dividend of $455,048.
Revenues of $204,664, for services related to vaccine and adjuvant technologies
were recognized during the three months ended March 31, 1998. No revenues were
recorded for the same period in the prior year.
General and administrative expenses were $536,921 for the three months ended
March 31, 1998 compared to $642,253 incurred for the same period in 1997. A
decrease in the non-cash compensation expense related to non-employee options
and warrants granted during 1998, along with decreased legal and other overhead
costs accounted for most of the $105,332 decrease.
Research and development expenses were $594,379 and $601,623 for the three
months ended March 31, 1998 and 1997, respectively. Total research and
development expenses exclusive of non-cash charges related to the below-market
priced stock options issued December 12, 1995 were $592,445 and $484,905 for
the periods ended March 31, 1998 and 1997, respectively. This increase of
$107,540 is related to the number of products in clinical trials and the nature
of those trials, including the number of patients and the duration of the
trials.
Net interest income of $93,037 was recorded in the three months ended March 31,
1998 compared with net interest income of $34,254 in the three months ended
March 31, 1997. The $58,783 increase is due to higher average cash balances
during the first quarter 1998, when compared to average cash balances during
the same period in 1997.
Liquidity and Capital Resources
Novavax's capital requirements depend on numerous factors, including but not
limited to the progress of its research and development programs, the progress
of preclinical and clinical testing, the time and costs involved in obtaining
regulatory approvals, the costs of filing, prosecuting, defending and enforcing
any patent claims and other intellectual property rights, competing
technological and market developments, and
7
<PAGE> 9
NOVAVAX, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS
changes in Novavax's development of commercialization activities and
arrangements. The Company has three product candidates in clinical trials.
Future activities including clinical development and the establishment of
commercial-scale manufacturing capabilities are subject to the Company's
ability to raise funds through equity financing, or collaborative arrangements
with corporate partners.
The Company used $772,598 of its cash resources during the three month period
ended March 31, 1998 to fund the activities of its research and development
programs and costs associated with obtaining regulatory approvals, pre-clinical
and clinical testing. In addition to revenues of $204,664, Novavax received
proceeds of $122,100 from the exercise of stock options and proceeds, net of
all related transaction costs, of $5,997,599 from the sale of 6,500 shares of
Series A Convertible Preferred Stock. The closing of the Preferred Stock
private placement occurred on January 28, 1998 at an aggregate price of
$6,500,000.
Cash and cash equivalents on March 31, 1998 totaled $9,188,116. Novavax
estimates that based on historical levels of spending, existing cash resources
will be sufficient to finance its operations for approximately 21 to 24 months
from March 31, 1998. Past spending levels are not necessarily indicative of
future spending. Future expenditures for product development especially related
to outside testing and human clinical trials are discretionary and,
accordingly, can be adjusted to available cash. As the company continues to
progress in its clinical development activities and commercial scale-up of
product manufacturing, it anticipates increases in spending associated with
these activities. Cash balances at March 31, 1998 should provide sufficient
resources to finance its operations and any anticipated increased spending
levels for approximately 17 to 20 months from March 31, 1998.
Moreover, the Company will seek to establish one or more collaborations with
industry partners to defray the costs of clinical trials and other related
activities. Novavax will also consider sources of additional funds through
public or private equity or debt financings, collaborative arrangements with
pharmaceutical companies or from other sources. There can be no assurance that
additional funding or bank financing will be available at all or on acceptable
terms to permit successful commercialization of Novavax's technologies and
products. If adequate funds are not available, Novavax may be required to
significantly delay, reduce the scope of or eliminate one or more of its
research or development programs, or seek alternative measures including
arrangements with collaborative partners or others that may require Novavax to
relinquish rights to certain of its technologies, product candidates or
products.
8
<PAGE> 10
NOVAVAX, INC. AND SUBSIDIARIES
PART II OTHER INFORMATION
Item 1 - Legal Proceedings
None
Item 2 - Changes in Securities
In order to provide the Company with additional capital, the Company privately
sold 6,500 shares of Series A Custom Convertible Preferred Stock, $.01 par
value per share (the "Series A Preferred Stock") for a total purchase price of
$6,500,000 pursuant to the terms of Subscription Agreements dated as of January
23, 1998 between the Company and each of four purchasers (the "Purchasers").
The closing of the sale of the Series A Preferred Stock to the Purchasers
occurred on January 28, 1998 (the "Issuance Date"). The terms of the Series A
Preferred Stock are contained in the company's Certificate of Designations (the
"Certificate of Designations") as filed with the Secretary of State of Delaware
on the Issuance Date. The Series A Preferred Stock is convertible into shares
of the company's Common Stock at any time at the election of the Purchasers.
The Series A Preferred Stock, with a purchase price of $1,000 per share, is
convertible into shares of Common Stock at a conversion price equal to (i)
during a period of 90 days following the Issuance Date (expiring on April 28,
1998), 100% of the lowest arithmetic average of the lowest sale price of the
Common Stock on each of two consecutive trading days during the 25 consecutive
trading days immediately preceding the conversion date as reported on the
American Stock Exchange (the "Two Day Average Trading Price") or (ii) during
the period on and after the date which is 91 days after the Issuance Date, 94%
of the Two Day Average Trading Price (the "Conversion Price"). The Conversion
Price has a ceiling price of $6.33 per share and, within the first 180 days
after the Issuance Date, applicable floor prices based on conversion dates. The
number of shares of Common Stock issuable upon conversion is determined by
dividing $1,000 plus an accrual amount through the conversion date equal to 5%
of such $1,000 amount per annum (the "Accrual Amount") by the Conversion Price.
As further described in the Certificate of Designations, the shares of Series A
Preferred Stock rank senior to the Common Stock and any other series or class
of preferred stock of the Company, now or hereafter issued, as to payment of
dividends (when, as and if declared by the Board of Directors out of funds
legally available for such purpose), and distribution of assets upon
liquidation, dissolution or winding up of the Company, whether voluntary or
involuntary. The shares of Series A Preferred Stock are not entitled to vote on
any matter except as otherwise required by law or as expressly provided in the
Certificate of Designations, which includes the requirement of the affirmative
vote of a majority (and in some instances the unanimous vote) of outstanding
shares of Series A Preferred Stock, voting separately as a class, for any
amendments or modifications to the Certificate of Incorporation which would
materially
9
<PAGE> 11
NOVAVAX, INC. AND SUBSIDIARIES
PART II OTHER INFORMATION
and adversely affect the powers, preferences, and rights of the Series A
Preferred Stock or create or issue senior dividend or senior liquidation stock.
As required by the Subscription Agreements, the Board of Directors has reserved
up to 2,406,350 shares of its authorized Common Stock for issuance of the
Conversion Shares and has listed that number of shares on the American Stock
Exchange (which number includes 200,000 additional shares of Common Stock which
may be issuable upon exercise of previously issued warrants, the antidilution
provisions of which are triggered by the conversion of the Series A Preferred
Stock). On February 20, 1998 the Company registered 2,206,350 shares of Common
Stock with the Securities and Exchange Commission in accordance with the
Subscription Agreements. The Subscription Agreements and the rules of the
American Stock Exchange require the Company to request stockholder approval for
the issuance of shares totaling 20% or more of the company's outstanding Common
Stock if such shares may be sold for less than the greater of their book or
market value. Assuming all 6,500 shares of Series A Preferred Stock were
converted and no floor price is in effect at the time, and excluding the
Accrual Amount (which amount varies depending on the conversion date), if the
Conversion Price was at or below $2.70, the aggregate number of Conversion
Shares that the Company would be obligated to issue would equal or exceed 20%
of the number of shares of Common Stock outstanding as of the Issuance Date.
Mandatory Redemption. If the company's stockholders do not approve the issuance
of shares totaling 20% or more of the company's outstanding Common Stock for
less than the greater of book or market value ("Stockholder Approval"), the
Company is not required to issue, upon conversion of the Series A Preferred
Stock, more than 2,406,350 shares of Common Stock (the "Maximum Share Amount").
The stockholders were asked to vote on this matter at the annual meeting of
stockholders to be held Thursday, May 14, 1998, in the notice of meeting and
proxy statement sent to stockholders on April 10, 1998. The holders of Series A
Preferred Stock will have the right to compel the Company to redeem that
portion of Series A Preferred Stock which is not convertible because of such
Maximum Share Amount limitation at a redemption price equal to 115% of (i)
$1,000 (the original purchase price of the Series A Preferred Stock) and (ii)
the Accrual Amount through the redemption date.
In addition to the mandatory redemption based on the Maximum Share Amount as
described in the preceding paragraph, the Certificate of Designations also
provides that, absent Stockholder Approval prior to June 30, 1998, the holders
of the Series A Preferred Stock may compel the Company to redeem up to
approximately 15% of their outstanding shares of Series A Preferred Stock at a
price equal to 105% of (i) $1,000 (the original purchase price of the Series A
Preferred Stock) and (ii) the Accrual Amount through the redemption date.
10
<PAGE> 12
NOVAVAX, INC. AND SUBSIDIARIES
PART II OTHER INFORMATION
Optional Redemption. Upon the occurrence of certain other events, including
among other things the default by the Company of any material obligation to the
holders of Series A Preferred Stock under the Subscription Agreements and the
Certificate of Designations, or certain business combinations entered into by
the Company, the holders of the Series A Preferred Stock may compel the Company
to redeem all or any portion of the Series A Preferred Stock at prices greater
than the original purchase price of such Series A Preferred Stock, such premium
prices being dependent upon the nature and timing of the optional redemption
event.
Item 3 - Defaults upon Senior Securities
None
Item 4 - Submission of Matters to a Vote of Security Holders
None
Item 5 - Other information
None
Item 6 - Exhibits and Reports on Form 8-K
(a) Exhibits:
Exhibit 27 - Financial Data Schedule
(b) Reports on Form 8-K:
None
11
<PAGE> 13
NOVAVAX, INC. AND SUBSIDIARIES
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
NOVAVAX, INC.
(Registrant)
Date: May 11, 1998 By:
---------------------------------
Brenda L. Fugagli
Senior Vice President, Chief Financial Officer
(Principal Financial and Accounting Officer)
12
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-END> MAR-31-1998
<CASH> 9,188,116
<SECURITIES> 0
<RECEIVABLES> 176,679
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 9,544,792
<PP&E> 1,562,790
<DEPRECIATION> (574,148)
<TOTAL-ASSETS> 12,118,733
<CURRENT-LIABILITIES> 272,658
<BONDS> 0
0
5,997,599
<COMMON> 120,827
<OTHER-SE> 0
<TOTAL-LIABILITY-AND-EQUITY> 12,118,733
<SALES> 204,664
<TOTAL-REVENUES> 204,664
<CGS> 0
<TOTAL-COSTS> 1,131,300
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (833,599)
<INCOME-TAX> 0
<INCOME-CONTINUING> (833,599)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (833,599)
<EPS-PRIMARY> (0.07)
<EPS-DILUTED> (0.07)
</TABLE>
